This video segment discusses the efficacy and safety profile of adagrasib for KRAS-positive metastatic NSCLC, drawing insights from the KRYSTAL-1 trial data to inform treatment sequencing decisions.
Video content above is prompted by the following:
Stay up to date on recent advances in the multidisciplinary approach to cancer.